Physician profile
Daniel Merck
NPI 1164080669
$442.34
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.81 · 2020: $202 · 2021: $60.93 · 2022: $93.04.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $120.59 | 2020-2021 | |
| Pfizer INC. | $92.45 | 2019-2020 | |
| Novo Nordisk INC | $67.21 | 2019-2021 | |
| Horizon Therapeutics Plc | $45.35 | 2022 | |
| Hologic Sales and Service, LLC | $35.28 | 2020 | |
| Abbvie INC. | $29.92 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.60 | 2019 | |
| Zealand Pharma US, INC. | $17.77 | 2022 | |
| Lundbeck LLC | $14.17 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Merck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.